Crk (phospho-Tyr-251) Blocking Peptide
€155.00
In stock
SKU
ECM-CX3095
Background:
The Crk family of adaptor proteins (Crk I, Crk II and CrkL) are Src Homology 2 (SH2) and Src Homology 3 (SH3) domain-containing proteins that form protein complexes important for transmiting signals downstream of tyrosine kinases. Both Crk II and CrkL are composed of a single SH2 domain, followed by two tandem SH3 domains. Crk II is also alternatively spliced to a minor product, Crk I, which is structurally and functionally more similar to the v-Crk oncogene. Both Crk II and CrkL are ubiquitously expressed and their SH domains are highly homologous, however both are required for mouse development and have distinct non-overlapping phenotypes in knockout mice. Phosphorylation may be important for regulating Crk activity. Crk II Tyr-221 (CrkL Tyr-207) phosphorylation is a negative regulatory site, while Crk Tyr-251 phosphorylation in the SH3 domain is a positive regulatory site. EGF stimulation induces phosphorylation of Tyr-251, which increases binding of Crk to the SH2 domain of Abl, and promotes transactivation of Abl.
Sequence: Phospho-Crk (Tyr-251) synthetic peptide corresponding to amino acid residues surrounding Tyr-251 in human Crk II. This peptide sequence is well conserved in mouse and rat Crk II, as well as in CrkL (Tyr-251). The site is not found in Crk I.
Specificity: The peptide is specifically recognized by anti-Crk (Tyr-251) phospho-specific antibody (CP3091) in ELISA, and has been shown to block the reactivity of CP3091 during Western blot. In addition, the peptide is recommended for use in blocking CP3091 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
The Crk family of adaptor proteins (Crk I, Crk II and CrkL) are Src Homology 2 (SH2) and Src Homology 3 (SH3) domain-containing proteins that form protein complexes important for transmiting signals downstream of tyrosine kinases. Both Crk II and CrkL are composed of a single SH2 domain, followed by two tandem SH3 domains. Crk II is also alternatively spliced to a minor product, Crk I, which is structurally and functionally more similar to the v-Crk oncogene. Both Crk II and CrkL are ubiquitously expressed and their SH domains are highly homologous, however both are required for mouse development and have distinct non-overlapping phenotypes in knockout mice. Phosphorylation may be important for regulating Crk activity. Crk II Tyr-221 (CrkL Tyr-207) phosphorylation is a negative regulatory site, while Crk Tyr-251 phosphorylation in the SH3 domain is a positive regulatory site. EGF stimulation induces phosphorylation of Tyr-251, which increases binding of Crk to the SH2 domain of Abl, and promotes transactivation of Abl.
Sequence: Phospho-Crk (Tyr-251) synthetic peptide corresponding to amino acid residues surrounding Tyr-251 in human Crk II. This peptide sequence is well conserved in mouse and rat Crk II, as well as in CrkL (Tyr-251). The site is not found in Crk I.
Specificity: The peptide is specifically recognized by anti-Crk (Tyr-251) phospho-specific antibody (CP3091) in ELISA, and has been shown to block the reactivity of CP3091 during Western blot. In addition, the peptide is recommended for use in blocking CP3091 reactivity in immunocytochemistry.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
| Is Featured? | No |
|---|
Write Your Own Review